| 罗 星,陈 琪,潘 博,傅剑锋,胡羽萌.康莱特注射液联合GP方案对晚期非小细胞肺癌患者免疫功能、新生血管生成和血清JAK2/STAT3信号通路的影响[J].,2022,(22):4395-4400 |
| 康莱特注射液联合GP方案对晚期非小细胞肺癌患者免疫功能、新生血管生成和血清JAK2/STAT3信号通路的影响 |
| Effects of Kanglaite Injection Combined with GP Regimen on Immune Function, Angiogenesis and Serum JAK2 / STAT3 Signal Pathway in Patients with Advanced Non-Small Cell Lung Cancer |
| 投稿时间：2022-03-26 修订日期：2022-04-22 |
| DOI：10.13241/j.cnki.pmb.2022.22.038 |
| 中文关键词: 康莱特注射液 GP方案 晚期非小细胞肺癌 免疫功能 新生血管生成 JAK2/STAT3信号通路 |
| 英文关键词: Kanglaite injection GP regimen Advanced non-small cell lung cancer Immune function Angiogenesis JAK2/STAT3 signal pathway |
| 基金项目:国家中医药管理局第六批全国老中医药专家学术经验继承项目（2017-29） |
|
| 摘要点击次数: 450 |
| 全文下载次数: 238 |
| 中文摘要: |
| 摘要 目的：探讨康莱特注射液联合吉西他滨联合顺铂（GP）方案对晚期非小细胞肺癌（NSCLC）患者免疫功能、新生血管生成和血清两面神激酶2（JAK2）/信号转导及转录活化因子3（STAT3）信号通路的影响。方法：选取2019年2月至 2020年2月期间湖南省中医药研究院附属医院收治的80例晚期NSCLC患者。根据随机数字表法分为对照组（GP化疗，n=40）和观察组（康莱特注射液联合GP化疗，n=40），治疗后观察两组患者疗效、免疫功能、新生血管生成指标、JAK2/STAT3信号通路相关指标的变化，记录不良反应发生率，并随访2年观察患者生存预后情况。结果：对照组、观察组的临床总有效率分别为60.00%（24/40）、82.50%（33/40），组间对比有统计学差异（P>0.05）。与对照组相比，观察组治疗后的CD8+更低，CD3+、CD4+、CD4+/CD8+更高（P<0.05）。与对照组相比，观察组治疗后的血管内皮生长因子（VEGF）进一步下降，组织抑制因子-2（TIMP-2）进一步升高（P<0.05）。与对照组相比，观察组治疗后的JAK2mRNA、STAT3mRNA进一步下降（P<0.05）。两组不良反应发生率组间对比，统计学无差异（P>0.05）。观察组中位生存期为19个月明显长于对照组的10个月，差异有统计学意义（P<0.05）。结论：康莱特注射液联合GP方案用于晚期NSCLC患者，可在一定程度上阻止疾病进展，减轻免疫抑制，延长生存期，考虑可能与下调JAK2/STAT3信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Kanglaite injection combined with gemcitabine and cisplatin (GP) regimen on immune function, angiogenesis and serum Janus kinase 2 (JAK2) / signal transducer and activator of transcription 3 (STAT3) signal pathway in patients with advanced non-small cell lung cancer (NSCLC). Methods: 80 patients with advanced NSCLC admitted to the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine from February 2019 to February 2020 were selected.According to the random number table method, they were divided into control group (GP chemotherapy, n=40) and observation group (Kanglaite injection combined with GP chemotherapy, n=40). After treatment, the efficacy, immune function, angiogenesis indexes and JAK2/STAT3 signal pathway related indexes changes of the two groups were observed, and the incidence of adverse reactions was recorded, the patients were followed up for 2 years to observe the survival and prognosis. Results: The total clinical effective rates of the control group and the observation group were 60.00% (24/40) and 82.50% (33/40) respectively, there was significant difference between the two groups (P>0.05). Compared with the control group, CD8+ was lower, CD3+, CD4+ and CD4+/CD8+ were higher in the observation group after treatment (P<0.05). Compared with the control group, vascular endothelial growth factor (VEGF) was further decreased, and tissue inhibitor of metalloproteinase-2 (TIMP-2) was further increased in the observation group after treatment (P<0.05). Compared with the control group, JAK2mRNA and STAT3mRNA in the observation group after treatment were further decreased (P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). The median survival of the observation group was 19 months, which was significantly longer than 10 months of the control group, and the difference was statistically significant (P<0.05). Conclusion: Kanglaite injection combined with GP regimen for patients with advanced NSCLC can prevent disease progression to a certain extent, alleviate immunosuppression and prolong survival, which may be related to down-regulation of JAK2/STAT3 signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
